Schott Pharma achieved a record year of growth in the fiscal year 2022, with generated sales of €821 million.

In the fiscal year 2022*, Schott Pharma's sales increased by 27% compared to the previous year.

Profitability also increased, resulting in an EBITDA up 33% to €219 million, and an EBITDA margin increase of 1.4 percentage points to 26.7%.

Andreas Reisse, CEO at Schott Pharma, said: “We expect the addressable market to increase annually by 7-8% in the following years.

“In particular, we saw a rising demand for our strong-margin high-value solutions, such as prefillable glass and polymer syringes, as well as ready-to-use containment solutions.”


Schott Pharma produced approximately 13 billion units for the pharma industry in the last fiscal year to safely store and administer medications.

The portfolio includes prefillable glass and polymer syringes, cartridges, vials, and ampoules.

Every minute, more than 25,000 people around the world receive an injection with medication filled in a Schott Pharma product.

Overall, Schott Pharma benefits from the strong growth of the market for injectables, which makes up one of the most dynamic segments in the industry.

“Looking ahead, we are expecting to continue to outperform the market growth,” said Reisse.

The company plans to further strengthen its business with high-value solutions. For example, ready-to-use (RTU) containers, which are pre-washed and pre-sterilised to allow pharma companies to start filling their drugs immediately.

While such prefillable syringes have been in the industry for decades, RTU vials and cartridges are well established for clinical trials and first commercial drugs.

Schott Pharma is seeing increasing demand from its customers to use these solutions also for commercial drug production and is prepared to meet the shift in demand towards RTU solutions.

There is also promise in prefillable polymer syringes for mRNA-based medications, which often must be stored at temperatures of -80 degrees Celsius.

“To our knowledge, we are the only supplier to offer a syringe system to meet these requirements,” said Reisse.

*The fiscal year 2022 runs from October 2021 to September 2022. The financial results in this article are unaudited combined financials.